drugset / Trial / NCT03188848
Dose Escalating Study of BPI-3016 in Healthy Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, dose finding study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneously injected BPI-3016 in Chinese healthy subjects.
Timeline
- Start
- 2017-05-24
- Primary completion
- 2019-07
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BPI-3016 | Unknown | 0.6 mg | Subcutaneous |
Indications
No indication recorded.